Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clopidogrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 known ✓ | Q9H244 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.98 |
| ▸ | DRD1 | P21728 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | THRB | P10828 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopidogrel SCHEMBL2087706 | 0.99 | ABCB11 (0.96) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL30388817 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL5567933 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031641 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL14009483 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL4769 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL29793709 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL1031319 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL754557 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 | |
| Clopidogrel SCHEMBL19148648 | 0.99 | ABCB11 (1.00) | ABCB11OPRM1ADRA2ACYP2B6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1837337-B1 | Novel crystalline polymorphs of clopidogrel | GENERICS UK LTD (GB) | 2016-04-06 | — | — | EP | claimed |
| EP-1772456-B1 | Novel crystalline polymorphs of clopidogrel | GENERICS UK LTD (GB) | 2014-10-29 | — | — | EP | claimed |
| US-7897613-B2 | Crystalline polymorphs of clopidogrel | GENERICS [UK] LIMITED (GB) | 2011-03-01 | — | — | US | claimed |
| EP-1618113-B1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | GENERICS UK LTD (GB) | 2010-11-10 | — | — | EP | claimed |
| EP-2149578-A1 | Novel crystalline polymorphs of clopidogrel | Merck Generics (UK) Limited (GB) | 2010-02-03 | — | — | EP | claimed |
| WO-2008004249-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CLOPIDOGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2008-01-10 | — | — | WO | claimed |
| US-20070281964-A1 | Novel Crystalline Polymorphs of Clopidogrel | GENERICS [UK] LIMITED (GB) | 2007-12-06 | — | — | US | claimed |
| EP-1837337-A1 | Novel crystalline polymorphs of clopidogrel | Merck Generics (UK) Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| EP-1772456-A1 | Novel crystalline polymorphs of clopidogrel | Generics (UK) Limited (GB) | 2007-04-11 | — | — | EP | claimed |
| EP-1618113-A1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | Generics (UK) Limited (GB) | 2006-01-25 | — | — | EP | claimed |
| WO-2005026174-A1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | GENERICS [UK] LIMITED (GB) | 2005-03-24 | — | — | WO | claimed |
| CN-109316452-B | Clopidogrel hydrogen sulfate freeze-dried orally disintegrating tablet | 北京兴源联合医药科技有限公司 | 2021-07-30 | — | — | CN | disclosed |
| EP-1837337-B1 | Novel crystalline polymorphs of clopidogrel | GENERICS UK LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| EP-1772456-B1 | Novel crystalline polymorphs of clopidogrel | GENERICS UK LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2012123958-A1 | HIGHLY PURE SALTS OF CLOPIDOGREL FREE OF GENOTOXIC IMPURITIES | CADILA HEALTHCARE LIMITED (IN) | 2012-09-20 | — | — | WO | disclosed |
| EP-1837337-A1 | Novel crystalline polymorphs of clopidogrel | Merck Generics (UK) Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| EP-1772456-A1 | Novel crystalline polymorphs of clopidogrel | Generics (UK) Limited (GB) | 2007-04-11 | — | — | EP | disclosed |
| EP-1674468-A1 | Polymorphs of clopidogrel hydrobromide | Ratiopharm GmbH (DE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1618113-A1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | Generics (UK) Limited (GB) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005026174-A1 | NOVEL CRYSTALLINE POLYMORPHS OF CLOPIDOGREL | GENERICS [UK] LIMITED (GB) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281964-A1 | Novel Crystalline Polymorphs of Clopidogrel | PDGFRB, PLAT, PTAFR | P2RY12 15/4885ABCB11 1092/4885OPRM1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.